Thursday 16 October, 2025
Objectives: Omalizumab, a recombinant humanized monoclonal antibody, is the first approved anti-IgE agent indicated in the US for adults and…
Read morePoster: Other Drug/Disease Modelling
PK-PD Modeling using 4β-Hydroxycholesterol to Predict CYP3A Mediated Drug Interactions
Thursday 16 October, 2025
Objectives: Develop a semi-mechanistic PK-PD model for the effects of rifampin and ketoconazole on CYP3A mediated formation of plasma 4b-hydroxycholesterol….
Read moreA population pharmacokinetics and pharmacodynamics of oseltamivir and oseltamivir carboxylate in adults and children infected with influenza virus A(H1N1)pdm09
Thursday 16 October, 2025
Objectives: Our objective was to characterize the population pharmacokinetics and pharmacodynamics of oseltamivir and its active metabolite oseltamivir carboxylate in…
Read morePKPD modelling of PGE2 inhibition and dose selection of a novel COX-2 inhibitor in humans.
Thursday 16 October, 2025
Objectives: The assessment of the analgesic effect of NCEs is primarily based on qualitative behavioral measures of pain [1]. This…
Read moreModel-based evaluation of iron overload in patients affected by transfusion dependent diseases
Thursday 16 October, 2025
Objectives: Patients affected by transfusion-dependent diseases who suffer from iron overload resulting from life-long blood transfusion require chelation therapy for…
Read moreDevelopment of a Bayesian Estimator for Tacrolimus in Kidney Transplant Patients: A Population Pharmacokinetic approach.
Thursday 16 October, 2025
Objectives: The aims of this study were (1) to develop a population pharmacokinetic (PPK) model for tacrolimus (TAC) in renal…
Read morePopulation pharmacokinetic model of sildenafil describing first-pass effect to its metabolite
Thursday 16 October, 2025
Objectives: Recently, many comparative pharmacokinetic (PK) studies are conducted in Korea using Viagra® (Pfizer Inc., NY, USA) as the reference…
Read moreModeling Early Viral Kinetics with Alisporivir: Interferon-free Treatment and SVR Predictions in HCV G2/3 patients
Thursday 16 October, 2025
Objectives: Alisporivir (ALV) is a cyclophilin inhibitor with pan-genotypic activity against hepatitis C virus (HCV). We characterized viral kinetics (VK)…
Read moreA Population Pharmacokinetic-Pharmacodynamic Analysis of Fimasartan in Patients with Mild to Moderate Essential Hypertension
Thursday 16 October, 2025
Objectives: Fimasartan is a novel nonpeptide angiotensin II receptor antagonist with a selective AT1 receptor blockade effect. The objective of…
Read moreMathematical Modelling of the Spread of Hepatitis C among Drug Users, effects of heterogeneity.
Thursday 16 October, 2025
Objective: We develop the model of Corson et al. [1] to study the effects of heterogeneity in spread HCV among…
Read more